Nemysis
Nemysis Limited is a Dublin-based specialty pharmaceutical company developing proprietary nanoparticulate iron supplements (IHAT) and glutenase enzymatic therapy (E40) for iron deficiency anemia, celiac disease, and non-celiac gluten sensitivity, commercializing through distribution partners across Italy and the Nordic region.
- Company typePrivate
- Founded2014
- HeadquartersDublin, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nemysis does
Nemysis Limited is a Dublin-based specialty pharmaceutical company founded in 2014, focused on developing proprietary therapeutic solutions for gut-mediated disorders and nutritional deficiencies, specifically iron deficiency/anemia and gluten intolerance. The company operates three technology platforms: IHAT (Iron Hydroxide Adipate Tartrate), a nanoparticulate iron supplement designed as a ferritin mimic that is absorbed as whole nanoparticles, avoiding gastrointestinal side effects common to conventional iron supplements; E40 (Endoprotease 40), a late-stage fast-acting glutenase produced via recombinant technology from Actinoallomurus A8, designed to break down all immunotoxic epitopes of α-gliadin in the stomach and small intestine as an adjunct to gluten-free diets for celiac disease and non-celiac gluten sensitivity; and EDA, an early-stage hyaluronic acid-based delivery matrix providing gastro-protection to enzymes and other compounds. IHAT became the first EFSA-assessed and EU-authorized nanomaterial for human iron supplementation, included under Regulation (EU) 2024/248 in June 2024.
Nemysis commercializes its products through a multi-channel distribution model including direct sales under its own Tolfer brand in Italy, non-exclusive agreements with Bruno Farmaceutici and Kolinpharma (Kipfer brand) for the Italian market, and Avia Pharma AB for Nordic region distribution covering Finland, Sweden, Norway, Denmark, and Germany. Revenue mechanics appear to combine licensing/royalty arrangements with channel partner sales. The company has established Italian subsidiary Nemysis S.r.l. (2020) and US subsidiary Enteralia Bioscience LLC (2021, Boston) to support regional commercialization and R&D, and co-founded the European Healthcare Alliance (EHA) in 2026 as a digital business development platform. End customers are fragmented patient populations: approximately 2 billion people globally with iron deficiency and approximately 80 million with celiac disease plus 480 million with NCGS, representing large addressable markets in nutraceutical and pharmaceutical categories. Total disclosed funding raised is approximately €5.15 million across a 2020 financing round, 2023 EIC Horizon grant, and undisclosed strategic investments from Avia Pharma and Kolinpharma in 2025.
Nemysis firmographics
Firmographics- Name
- Nemysis
- Legal name
- Nemysis Limited
- Website
- https://nemysisltd.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nemysis Limited is a Dublin-based specialty pharmaceutical company developing proprietary nanoparticulate iron supplements (IHAT) and glutenase enzymatic therapy (E40) for iron deficiency anemia, celiac disease, and non-celiac gluten sensitivity, commercializing through distribution partners across Italy and the Nordic region.
- Ownership category
- akta.pro rank
Nemysis industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Food (Health) Supplement Retailers (456191)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Nutrition & Malabsorption (Celiac/Short Bowel) (HLAKAEAI)
- akta.pro secondary industry
- Gut Health & Digestive Nutrition (IBS, GERD, Elimination Diets) (HSADAFAH)
Keywords
Where Nemysis is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices3 records
Markets served
Nemysis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- IHAT Oral Iron Supplement: Nemysis commercializes IHAT through distribution partners internationally. Kolinpharma commercializes IHAT under its own trademark Kipfer in Italy. Bruno Farmaceutici markets IHAT under its own brand in Italy. Avia Pharma distributes IHAT in Nordic regions. Nemysis directly markets IHAT under its own brand Tolfer within Italy.
- E40 Glutenase (Endoprotease 40): Late-stage development product targeting celiac disease and NCGS. Currently completing development and initial commercial manufacturing with funding from current investment round.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Nemysis product offering
Product offeringCore offering
Nemysis is a Dublin-based specialty pharmaceutical company developing proprietary therapeutic solutions for gut-mediated disorders and nutritional deficiencies. Its lead commercial product is IHAT (Iron Hydroxide Adipate Tartrate), a novel nanoparticulate iron supplement designed as a ferritin mimic for iron deficiency and anemia. The pipeline includes E40 (Endoprotease 40), a late-stage glutenase enzyme for celiac disease and non-celiac gluten sensitivity, and EDA, a hyaluronic-acid based delivery matrix for gastro-protection of enzymes. Products are commercialized via distribution partners and direct sale under the Tolfer brand.
Product overview
Nemysis is a Dublin-based Speciality Pharmaceutical Company developing proprietary therapeutic solutions for prevalent nutritional and gut-mediated disorders. The company operates three technology platforms: IHAT (Iron Hydroxide Adipate Tartrate), a nano-iron supplement for iron deficiency and anemia; E40 (Endoprotease 40), an oral glutenase for celiac disease and gluten sensitivity; and EDA, a novel delivery matrix for gastro-protection of enzymes. The products address large unmet needs in gut-mediated disorders while avoiding gastrointestinal side effects and microbiome damage common to existing treatments.
Differentiator
Problem solved
Functional benefit
Brands
- Tolfer: Nemysis' own brand for IHAT oral iron supplement marketed directly in Italy.
Products and services
- IHAT (Iron Hydroxide Adipate Tartrate) A novel and proprietary nanoparticulate chemical entity, the first EFSA-assessed and EU-authorised nano-iron for human use, designed as an organic acid-doped ferritin nanoparticle that mimics dietary iron absorption. It is used for safe and effective iron repletion in patients with iron deficiency and iron deficiency anemia, minimising gastrointestinal side effects common to conventional iron supplements.
- E40 (Endoprotease 40) A late-stage fast-acting glutenase produced under GMP conditions via recombinant technology, designed to be taken before meals to support gluten digestion as an adjunct to a Gluten-Free Diet. It targets patients with Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) to limit generation of Gluten Immunogenic Peptides and protect against inadvertent gluten exposure.
- EDA (Novel Delivery Matrix) An early-stage hyaluronic acid-based functionalized hydrogel delivery matrix designed to provide gastro-protection to enzymes and other compounds sensitive to the gastric environment, enabling their safe delivery beyond the stomach to the site of action or absorption in the intestine.
Quantifiable outcome
- E40 demonstrated ≥95% dose-dependent detoxification of whole gluten in real food matrices (bread, pasta) within 2 hours gastric phase
- +3 more outcomes
Companies that use Nemysis
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Nemysis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Nemysis partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- European Healthcare Alliance (EHA)coreEHA founded in 2026 by Nemysis Ltd., Enteralia Bioscience S.r.l., and Ricerchima S.r.l. to create a digital platform (www.eha-network.com) connecting companies and consultants across European healthcare sector covering pharmaceuticals, medical devices, food supplements, and cosmetics. Platform enables members to showcase assets for licensing, access qualified opportunities, and identify partners with focus on innovative healthcare products from outside EU entering European markets.
- Avia Pharma ABcoreCollaboration with Avia Pharma AB as IHAT distributor in Nordic region (Finland, Sweden, Norway, Denmark, Germany). Avia brings strong knowledge of markets across Northern Europe, complementing Nemysis' experience in Southern European markets.
- Kolinpharma S.p.A.coreIHAT Sales and Marketing Agreement signed with Kolinpharma S.p.A. for commercialization of IHAT in Italy under Kolinpharma's own trademark Kipfer.
- Bruno Farmaceutici S.p.A.coreNon-exclusive sales and marketing agreement for IHAT. Bruno Farmaceutici uses its existing sales network and relationships with relevant clinical communities to market IHAT under its own brand in Italy. Combined with Nemysis' direct marketing under Tolfer brand, these channels provide excellent coverage of the Italian market.
- Faran S.A.minorStrategic agreement to cooperate for the development of Endoprotease E40 for Celiac Disease. Faran is an Italian pharmaceutical company.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Nemysis competitors and assessment
Company assessmentDirect peers
- Shield Therapeutics: UK-listed specialty pharma commercializing Accrufer (ferric maltol), an oral iron therapy with novel mechanism and improved GI tolerability. Closest direct competitor to Nemysis's IHAT in differentiated oral iron supplementation for iron deficiency anemia.
- Pharmacosmos: Danish specialty pharma focused on iron deficiency treatments including MonoFerric (ferric derisomaltose) and Diafer. Directly competes in the iron deficiency/anemia therapeutic space with established European commercial footprint similar to Nemysis's distribution approach.
- ImmunogenX: US-based biotech developing latiglutenase (ALV003) for celiac disease — the closest direct competitor to Nemysis's E40 glutenase. Operates in the same glutenase enzymatic therapy category targeting celiac patients on a gluten-free diet.
- Scharper Pharmaceuticals: Italian nutraceutical and specialty pharma company previously led by Marco Cartolari (Nemysis COO). Highly comparable in Italian market focus, nutraceutical category positioning, and historical leadership overlap with Nemysis's commercialization approach.
- Dr. Falk Pharma: German specialty pharma focused exclusively on gastroenterology with a broad portfolio across IBD, hepatology, and gut disorders. Highly comparable in terms of specialty pharma focus on gastrointestinal conditions and European commercial model.
Broad incumbents
- CSL Vifor: Major player in iron deficiency with Ferinject/Injectafer (IV iron) and broader specialty pharma portfolio. While broader and primarily IV-focused, CSL Vifor defines the competitive context for differentiated iron therapies including IHAT.
- Alfasigma: Italian specialty pharma with significant gastroenterology and nutraceutical presence. Comparable in terms of Italian/European market footprint, specialty pharma focus, and overlapping therapeutic areas including gut disorders.
- Cosmo Pharmaceuticals: European specialty pharma with gastroenterology products (e.g., Aemcolo for traveler's diarrhea) and proprietary delivery platforms. Similar European specialty pharma profile and GI therapeutic focus as Nemysis.
- Abbott Nutrition: Global nutrition business within Abbott with iron supplements, pediatric nutrition, and adult nutrition products. Broader incumbent in nutrition/iron deficiency space; Estrella Bengio (Nemysis's Global Regulatory Affairs Head) previously served as Regulatory Affairs Director at Abbott Nutrition, illustrating the talent and category linkage.
Emerging players
- AnGes MG: Japanese biotech developing therapeutics across multiple indications including gastrointestinal disorders; comparable as an emerging specialty biotech with European/Asian clinical development focus and a pipeline of specialty therapeutics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Nemysis social profiles
Digital presenceNemysis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nemysis leadership team
Management profileNumber of profiles
Profiles12 records
Nemysis subsidiaries and ownership
Company hierarchySubsidiaries3 records
Nemysis funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nemysis M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nemysis
What does Nemysis do?
Nemysis is a Dublin-based specialty pharmaceutical company developing proprietary therapeutic solutions for gut-mediated disorders and nutritional deficiencies. Its lead commercial product is IHAT (Iron Hydroxide Adipate Tartrate), a novel nanoparticulate iron supplement designed as a ferritin mimic for iron deficiency and anemia. The pipeline includes E40 (Endoprotease 40), a late-stage glutenase enzyme for celiac disease and non-celiac gluten sensitivity, and EDA, a hyaluronic-acid based delivery matrix for gastro-protection of enzymes. Products are commercialized via distribution partners and direct sale under the Tolfer brand.
Is Nemysis a public or private company?
Nemysis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nemysis founded?
Nemysis was founded in 2014. It employs 1 to 10 people.
Where is Nemysis based?
Nemysis is headquartered in Dublin, Ireland, in the Europe region.
How does Nemysis make money?
Two revenue lines are on record. IHAT Oral Iron Supplement is the primary driver. The others are E40 Glutenase (Endoprotease 40).
Who are Nemysis's main competitors?
Direct peers on record are Shield Therapeutics, Pharmacosmos, ImmunogenX, Scharper Pharmaceuticals and Dr. Falk Pharma. Broad incumbents are CSL Vifor, Alfasigma, Cosmo Pharmaceuticals and Abbott Nutrition. AnGes MG is listed as an emerging player.
Does Nemysis have an API?
No public API is recorded for Nemysis.
What industry is Nemysis in?
Nemysis's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAKAEAI, Nutrition & Malabsorption (Celiac/Short Bowel), with a secondary code of HSADAFAH, Gut Health & Digestive Nutrition (IBS, GERD, Elimination Diets). Its NAICS code is 456191 and its SIC code is 5122.